Novo Nordisk announced the launch of a multi-month subscription program for its Wegovy obesity drug products on Tuesday, March 31, 2026. The program is designed to offer cash-paying patients lower and predictable monthly prices, with options for three-, six-, or twelve-month subscriptions covering both the Wegovy injection and the two highest doses of the newly launched pill under the same brand name. Longer subscription plans provide greater savings, with patients potentially saving up to $1,200 per year on the injection and up to $600 per year on the pill compared to paying for individual doses monthly [1].
The subscription pricing for Wegovy injections is set at $329 per month for a three-month plan (saving $240 per year), $299 per month for a six-month plan (saving $600 per year), and $249 per month for a twelve-month plan (saving $1,200 per year). For the pill, the three-month plan costs $289 per month (saving $120 per year), the six-month plan is $269 per month (saving $360 per year), and the twelve-month plan is $249 per month (saving $600 per year). Patients will pay flat monthly prices regardless of dose changes, and the program will be available through several telehealth partners, including Ro, WeightWatchers, LifeMD, Sesame, and Hims & Hers, with more partners expected to join soon [1].
Ed Cinca, Novo Nordisk's head of marketing and patient solutions, described the offering as an opportunity to help patients start and stay on therapy, addressing longstanding issues such as difficulty accessing GLP-1 drugs and gastrointestinal side effects. A 2025 study cited by Novo Nordisk estimated that around 65% of patients with obesity discontinue GLP-1 treatment within a year [1].
The launch of the subscription program comes as Novo Nordisk faces increasing competition from Eli Lilly, which is expected to introduce an oral GLP-1 later in 2026. Currently, Eli Lilly holds an estimated 60% share of the branded GLP-1 market in the U.S., while Novo Nordisk has about 39%. The Wegovy pill has seen rapid uptake since its U.S. launch in January, primarily attracting patients who had not previously used GLP-1 injections. Novo Nordisk aims to capture as many new patients as possible before Eli Lilly's competing product arrives [1].
Cash-paying patients can still pay $149 per month for the lower doses of the Wegovy pill (1.5 and 4 milligrams), but starting in August, the 4-milligram dose will increase to $199 per month. The recently approved 7.2-milligram dose will be added to the subscription program at a later date [1].
CONCLUSION
Novo Nordisk's launch of multi-month Wegovy subscription plans is a strategic move to retain and attract patients amid rising competition from Eli Lilly. The program offers significant savings and predictable pricing, addressing patient adherence challenges and market dynamics. With Eli Lilly poised to introduce a competing oral GLP-1 later this year, Novo Nordisk's initiative may help strengthen its market position in the rapidly evolving obesity drug sector.